Mycoplasma Testing Market to Notice Prominent Growth of USD 526.23 Million By 2030, Size, Share, Trends, Demand, Growth and Competitive Outlook

Data Bridge Market Research analyses that the mycoplasma testing market value is USD 295.06 million in 2022, is expected to reach USD 526.23 million by 2030, at a CAGR of 7.5% during the forecast period 2023 to 2030

MELBOURNE, May 24, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research has released a new report titled "Mycoplasma Testing Market" which delves deep into growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and competitive environment. A wide-ranging Mycoplasma Testing advertising report gives details about the top players and brands that are driving the market. This market report is a synopsis about how is the market status right now and how will it be in the forecast years for the Mycoplasma Testing industry. Also, this market report gives an in-depth knowledge of recent developments, and product launches are, while also keeping track of recent acquisitions, mergers, joint ventures and competitive research in the global market industry. The report provides awareness of all the drivers and restraints, which are derived through SWOT analysis. Mycoplasma Testing is a professional and detailed market report that highlights primary and secondary drivers, market share, leading segments, and geographical analysis.

Mycoplasma Testing report analyses the up-and-coming trends along with major drivers, challenges, and opportunities in the market. The current market scenario and future prospects of the sector have also been examined here. Further, it presents the company profile, product specifications, production value, contact information of the manufacturer, and market shares for the company. All the numerical data included in the report is backed up by excellent tools such as SWOT analysis, Porter's Five Forces Analysis, and others. The statistics are signified in graphical and tabular format for a clear understanding of facts and figures. The premium Mycoplasma Testing market report takes into consideration key market dynamics of the sector.

Data Bridge Market Research analyses that the mycoplasma testing market value is USD 295.06 million in 2022, and is expected to reach USD 526.23 million by 2030, at a CAGR of 7.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Grab a PDF Sample of the Mycoplasma Testing Market @

A mycoplasma test detects active or recent mycoplasma infections, and bacterial infections. Testing can be done in a variety of ways depending on which one is suspected because there are different types of mycoplasma infections. M. pneumonia, the most common Mycoplasma, causes upper respiratory infections and can be tested with a blood sample. Other mycoplasma tests may require the collection of a variety of samples, including sputum, joint fluid, body fluids, tissue samples, or a genital swab.

According to the CDC, the number of deaths from chronic lower respiratory diseases will be 152,657 in 2021. The number of deaths from respiratory illnesses, pulmonary disease, and tuberculosis has increased, and these figures are expected to rise further in the coming years, fuelling the growth of the mycoplasma testing market. Furthermore, key market participants anticipate an increase in demand for improved diagnostics for non-pulmonary therapies, which will drive the global market in the near future.


  • Globalization of clinical trials

The primary reasons pharmaceutical and biopharmaceutical companies choose to outsource clinical trials and R&D are cost efficiency, ease of patient recruitment, lower operating costs and less stringent regulatory frameworks than those found in the United States and Western Europe. Aside from cost savings, sponsors cite improved quality and reduced time to market as key reasons for outsourcing business functions to CROs, CDMOs, and CMOs.

Fundamental Aim of Mycoplasma Testing Market Report

In the Mycoplasma Testing market, every company has goals, but this report focus in on the most important ones, allowing you to gain insight into the competition, the future of the market, potential new products, and other useful information that can boost your sales significantly.

  • Major alterations to the Mycoplasma Testing Market in the near future.
  • Notable Market rivals around the world.
  • The Mycoplasma Testing Market's Future Scope and Product Outlook
  • Future-promising emerging markets.
  • The Market Presents Difficult Challenges and Threats.
  • Sales data and profiles of the world's leading Mycoplasma Testing players

The Mycoplasma Testing Market is Dominated by Firms Such as

  • AB ANALITICA s.r.l. (Italy)
  • BIOMÉRIEUX (France)
  • ELITechGroup (France)
  • Liofilchem S.r.l. (Italy)
  • Agilent Technologies, Inc. (U.S.)
  • PromoCell GmbH (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • OSANG Healthcare (South Korea)
  • Sacace Biotechnologies Srl (Italy)
  • Lonza (Switzerland)
  • Merck KGaA (Germany)
  • Seegene Inc. (South Korea)
  • Clongen Laboratories, LLC (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Charles River Laboratories (U.S.)
  • Bionique Testing Laboratories LLC (U.S.)
  • ZEAKON Diagnostics (India)

Download the Complete Research Study Here in PDF Format @

Recent Development

  • In 2020, Liofilchem S.r.l. introduced the AF Genital System, VTM, Lockable contact plates with improved microbial testing configuration. This product enhancement helped the company increase its revenue.
  • In 2020, BioMérieux SA announced the availability of the biofire mycoplasma test for the detection of mycoplasma in biopharmaceutical products. This initiative aided the company in increasing the use of its products in the biotherapeutics market.

The investment made in the study would provide you access to information such as:

  • Mycoplasma Testing Market [Global – Broken-down into regions]
  • Regional level split [North America, Europe, Asia Pacific, South America, Middle East & Africa]
  • Country-wise Market Size Split [of important countries with major market share]
  • Market Share and Revenue/Sales by leading players
  • Market Trends – Emerging Technologies/products/start-ups, PESTEL Analysis, SWOT Analysis, Porter’s Five Forces, etc.
  • Mycoplasma Testing Market Size
  • Market Size by Application/industry verticals
  • Market Projections/Forecast

Key Market Segments Covered in Mycoplasma Testing Industry Research


  • PCR
  • Direct Assays
  • Indirect Assays
  • DNA Staining
  • Microbial Culture Techniques
  • Enzymatic


  • Kits and Reagent
  • PCR assays
  • Nucleic acid detection kits
  • Elimination kits
  • Reagents
  • Stains
  • Standards
  • Controls
  • Others
  • Instruments


  • Cell Line Testing
  • Virus Testing
  • End-Of-Production Cell Testing

 End Users

  • Hospitals
  • Surgical Centers
  • Clinics
  • Community Healthcare

Distribution Channel

  • Retail
  • Direct Tenders

Browse More About This Research Report @

Key Growth Drivers:

  • Increasing R&D investments

Rising research costs and increased R&D investments by key companies will almost certainly encourage companies to use highly efficient mycoplasma testing tools. For instance, Bristol-Myers Squibb began investing in developing investigational medicines to support clinical trials. Furthermore, with the introduction of biosimilars and the resulting lucrative R&D investment, safety testing has become critical to ensure that a product meets the standards for efficacy, safety, and overall public health. Merck KGaA expanded its manufacturing footprint in the United States in December 2020, investing more than USD 45.6 million (EUR 40 million) in Massachusetts and New Hampshire production facilities. The facilities were built to produce a wide range of biopharmaceutical manufacturing products while also increasing the company's production capacity. This is expected to improve the mycoplasma testing market.

  • Innovative approaches and significant investments

As a result of innovative approaches and significant investments by operating players, the mycoplasma testing market is gaining traction. For instance, biologics accounted for seven of the top ten best-selling drugs in early 2020. This reflects the emergence of biologics in the global market. Cell lines are essential in the production of a wide range of biologic products, including monoclonal antibodies, viral vaccines, and cytokines, which are used for medicinal or therapeutic purposes. Mycoplasma strains greatly impact cell line metabolism, physiology, and gene expression. As a result, these are the certain factors which propel the mycoplasma testing market growth.

Mycoplasma Testing Market Regional Analysis/Insights:

The countries covered in the mycoplasma testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the mycoplasma testing market because of repeated purchases of consumables for the detection of mycoplasma in cell culture, the kits and reagents segment is expected to grow at the fastest rate during the forecast period of 2023 to 2030.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to increased demand for effective testing, the kits and reagents segment dominates the mycoplasma testing market.

The report provides insights on the following pointers:

  1. Market Penetration: Comprehensive information on the product portfolios of the top players in the Mycoplasma Testing market.
  2. Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market.
  3. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.
  4. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.
  5. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Mycoplasma Testing market

Table of Contents:

  1. Introduction
  2. Market Segmentation
  3. Executive Summary
  4. Premium Insights
  5. Global Mycoplasma Testing Market: Regulations
  6. Market Overview
  7. Global Mycoplasma Testing Market, By Technique
  8. Global Mycoplasma Testing Market, By Product
  9. Global Mycoplasma Testing Market, By Application
  10. Global Mycoplasma Testing Market, By End User
  11. Global Mycoplasma Testing Market, By Distribution Channel
  12. Global Mycoplasma Testing Market, By Region
  13. Global Mycoplasma Testing Market: Company Landscape
  14. SWOT Analyses
  15. Company Profile
  16. Questionnaires
  17. Related Reports

Get the Complete Table of Contents @

Explore More Reports:

  • Mycoplasma Genitalium Market, By Treatment (Antibiotics, Others), Diagnosis (Nucleic Acid Amplification Test (NAAT), Others), Symptoms (Watery discharge from penis, Burning, stinging, or pain when pee, Pain during sex, Discharge from vagina, Bleeding between periods, Bleeding after sex, Pain in pelvic area, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa)
  • Cold Plasma Market, By Regime Type (Low Pressure, Atmospheric Pressure), Technology (Remote Treatment Direct Treatment, Electrode Contact), Industry (Textile Industry, Polymer and Plastic & Plastic Industry, Electronics and Semiconductor & Plastic Industry, Food & Agriculture & Plastic Industry and Medical & Plastic Industry), Country (Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East & Africa)
  • Plasma Therapy Market, By Type (Pure PRP, Leucocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedics, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury, Others), End User (Hospitals and Clinics, Research Institutions), and Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa)
  • Blood Plasma Market, By Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin and  Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology and Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD) and Others), End User (Hospitals, Clinics, and Other)

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475